Trial Profile

A Phase 1b Study to Characterize the Pharmacokinetics of Evacetrapib and Potential for Accumulation After Dosing for 12, 24, and 52 Weeks

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 14 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Evacetrapib (Primary)
Indications Dyslipidaemias
Focus Pharmacokinetics
Sponsors Eli Lilly and Company

Most Recent Events

25 Jan 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
17 Dec 2015 Planned End Date changed from 1 Nov 2015 to 1 Jan 2016 as per Clinical trials.gov record.
17 Dec 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Jan 2016 as per Clinical trials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com